Orphan G-protein coupled receptor 183 (GPR183) potentiates insulin secretion and prevents glucotoxicity-induced β-cell dysfunction

J Taneera, I Mohammed, AK Mohammed… - Molecular and cellular …, 2020 - Elsevier
J Taneera, I Mohammed, AK Mohammed, M Hachim, S Dhaiban, A Malek, P Dunér…
Molecular and cellular endocrinology, 2020Elsevier
The expression and functional impact of most orphan G-protein coupled receptors (GPCRs)
in β-cell is not fully understood. Microarray expression indicated that 36 orphan GPCRs are
restricted in human islets, while 55 receptors overlapped between human islets and INS-1
cells. GPR183 showed higher expression in diabetic compared to non-diabetic human
islets. GPR183 expression co-localized with β-cells while it was lacking in α-cells in human
islets. The GPR183 agonist (7α-25-DHC) potentiated insulin secretion and protected against …
Abstract
The expression and functional impact of most orphan G-protein coupled receptors (GPCRs) in β-cell is not fully understood. Microarray expression indicated that 36 orphan GPCRs are restricted in human islets, while 55 receptors overlapped between human islets and INS-1 cells. GPR183 showed higher expression in diabetic compared to non-diabetic human islets. GPR183 expression co-localized with β-cells while it was lacking in α-cells in human islets. The GPR183 agonist (7α-25-DHC) potentiated insulin secretion and protected against glucotoxicity-induced β-cell damage in human islets. Silencing of GPR183 in INS-1 cells decreased the expression of proinsulin genes, Pdx1, Mafa and impaired insulin secretion with a concomitant decrease in cAMP generation. Cultured INS-1 cells with 7α-25-DHC were associated with increased proliferation and expression of GPR183, INS2, PDX1, NeuroD, and INSR. In conclusion, the beneficial impact of GPR183 activation on β-cell function makes it a potential therapeutic target to prevent or reverse β-cell dysfunction.
Elsevier
以上显示的是最相近的搜索结果。 查看全部搜索结果